-ADMA Biologics, Inc., a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention and treatment of certain infectious diseases, today announced its financial results for the year...
"Our fourth quarter and fiscal 2018 results are in line with our forecasts," said Graeme Duncan, Chief Executive Officer of ADVANZ PHARMA. Reported fourth quarter revenue of $117.6 million, compared to $150.2 million for the fourth quarter of 2017, and $127.7 million for the third quarter of 2018. Reported a net loss for the fourth quarter of 2018
Agency: " Food and Drug Administration, HHS." Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the no
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, will present the results from its open label study evaluating AKST4290 for the treatment of wet age-related macular degeneration in treatment-nave patients at the Retina World Congress in Fort Lauderdale, Florida
DUBLIN, March 14, 2019/ PRNewswire/ Allergan plc,, a leading global pharmaceutical company with more than 70 years of heritage in eye care, will present new data including a late-breaking abstract for Bimatoprost SR at the Annual Meeting of the American Glaucoma Society to be held in San Francisco, California. Logistic Regression Analysis of Base
Rockville, MD 03/14/2019 Alport Syndrome is the hereditary genetic disorder characterized by glomerulonephritis, abnormal vision, acute hearing loss and end-stage renal disease. Alport Syndrome is also called the hereditary nephritis. According to the National Institute of Health, alport syndrome occurs in approximately 1 in 50,000 newborns.
Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on recent developments in its business. "Aquestive made significant.
In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc., a late clinical-stage biopharmaceutical company with research ongoing in two kidney diseases, Lupus Nephritis and Focal Segmental Glomerulosclerosis, today announced a host of activities, including an initiative with The National Kidney Foundation, designed
Phase 1 trial confirmed superior bioavailability of intranasal betahistine as well as good safety and tolerability Intranasal betahistine program progressing towards proof-of-concept studies in acute vertigo and antipsychotic-induced weight gain Detailed results from HEALOS Phase 3 trial with Sonsuvi published in peer-reviewed journal Full...
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, today reported financial results for the fourth quarter and year ended December 31, 2018. In 2018, we advanced our clinical programs and significantly expanded our CNS pipeline through the add
WASHINGTON- Becton, Dickinson and Company announced the U.S. FDA has granted premarket approval for the Venovo venous stent, the first stent indicated to treat iliofemoral venous occlusive disease, which is obstructed or narrowed blood flow specific to the iliac and femoral veins located near the groin. We designed the Venovo venous stent in collab
BD, a leading global medical technology company, today announced the U.S. Food and Drug Administration has granted premarket approval for the Venovo? venous stent, the first stent indicated to treat iliofemoral venous occlusive disease, which is obstructed or narrowed blood flow specific to the iliac and femoral veins located near the groin.
Bempedoic acid is an oral, once-daily ATP Citrate Lyase Inhibitor that reduces cholesterol and fatty acid synthesis in the liver Study 1 is the largest of a comprehensive five Phase 3 study programme investigating the benefits of bempedoic acid in patients requiring additional low-density lipoprotein cholesterol lowering Over 52- weeks, bempedoic a
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has enrolled the first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in...
BrainStorm Cell Therapeutics Inc., a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the first patient has been enrolled in its Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous MSC-NTF cells in participants with...
Bruker Corporation today announced that it has acquired Arxspan LLC, a provider of cloud-based scientific software and workflow solutions, based in Southborough, Massachusetts. Commenting on the acquisition, Dr. Falko Busse, Group President for Bruker Biospin, stated: "The Arxspan acquisition, coupled with our strategic partnership with Mestrelab
The United States Food and Drug Administration, or FDA, has granted orphan drug, fast track and rare pediatric disease designations to edasalonexent for the treatment of DMD. The European Commission, or EC, has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. We initiated a global Phase 3 trial of edasalonexen
Solomon Page, a specialty niche provider of staffing solutions and executive search, announces the international expansion of Clinical Resource Network. Launched as a division of Solomon Page in 2002, CRN supports customized staffing solutions for a range of clients from Biotechs and CROs to pharmaceutical and medical device companies across N
FactMR has actively published a new research study titled Contract Pharmaceutical Fermentation Services Market Report through 2018-2026 to its broad online database. This assessment works to discourse the major trends, opportunities and drivers motivating the contract pharmaceutical fermentation services market during 2018-2026. The insights.
ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, today announced financial results for the fourth quarter and full year ended December 31, 2018.. 2018 was a milestone year for ContraFec
Albany, NY 03/14/2019 Contrast media are used to enhance quality of medical imaging such as CT, MRI, PET/CT and ultrasound. Their value has long been recognized by radiologists and is well illustrated by their frequent use in radiology departments worldwide. Contrast media injectors are devices employed for injecting contrast media into the b
-Correvio Pharma Corp.,, a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has entered into an At the Market Sales Issuance Agreement dated March 13, 2019 with Cantor Fitzgerald& Co. as agent, pursuant to which the Company may, from time to time sell, through "at-the-market" offerings on the Nasda
New York, NY 03/14/2019 CRISPR Market and Patent Landscape Report by Applications, by Products, by Technology, by Patent Activities Global Forecast, 2030.. Market Industry Reports has published a new report titled "CRISPR Technology Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 2030." According to the
ALACHUA, FL/ ACCESSWIRE/ March 14, 2019/ CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer's Disease. The Alzheimer's Association rep
Cue Biopharma, Inc., an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today that it will present a corporate overview at the Oppenheimer 29 th Annual Healthcare Conference on Tuesd